NO20063020L - Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer - Google Patents

Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer

Info

Publication number
NO20063020L
NO20063020L NO20063020A NO20063020A NO20063020L NO 20063020 L NO20063020 L NO 20063020L NO 20063020 A NO20063020 A NO 20063020A NO 20063020 A NO20063020 A NO 20063020A NO 20063020 L NO20063020 L NO 20063020L
Authority
NO
Norway
Prior art keywords
formulations
origin
ability
diseases
nmb1125
Prior art date
Application number
NO20063020A
Other languages
English (en)
Norwegian (no)
Inventor
Sonia Gonzalez Blanco
Gerardo Enrique Guillen Nieto
Rolando Pajon Feyt
Yasser Perera Negrin
Darien Garcia Diaz
Olivia Niebla Perez
Evelin Caballero Menendez
Gretel Sardinas Garcia
Lazaro Hiram Betancourt Nunez
Lila Rosa Castellanos Serra
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of NO20063020L publication Critical patent/NO20063020L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20063020A 2003-12-03 2006-06-28 Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer NO20063020L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20030285A CU23237A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
PCT/CU2004/000015 WO2005054281A2 (es) 2003-12-03 2004-12-02 Proteína nmb1125 y su uso en formulaciones farmaceuticas

Publications (1)

Publication Number Publication Date
NO20063020L true NO20063020L (no) 2006-09-01

Family

ID=40091628

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063020A NO20063020L (no) 2003-12-03 2006-06-28 Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer

Country Status (18)

Country Link
US (1) US7691971B2 (pl)
EP (1) EP1693378B9 (pl)
KR (1) KR20060123759A (pl)
CN (1) CN1890260A (pl)
AR (1) AR047263A1 (pl)
AT (1) ATE444305T1 (pl)
AU (1) AU2004294376A1 (pl)
BR (1) BRPI0417309A (pl)
CA (1) CA2547317A1 (pl)
CU (1) CU23237A1 (pl)
DE (1) DE602004023419D1 (pl)
ES (1) ES2334138T3 (pl)
NO (1) NO20063020L (pl)
NZ (1) NZ547520A (pl)
PL (1) PL1693378T3 (pl)
RU (1) RU2336900C2 (pl)
WO (1) WO2005054281A2 (pl)
ZA (1) ZA200604556B (pl)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
CN100379757C (zh) * 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
DK1185691T3 (da) 1999-04-30 2009-06-22 Novartis Vaccines & Diagnostic Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9911692D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic combinations

Also Published As

Publication number Publication date
CU23237A1 (es) 2007-09-26
EP1693378B1 (en) 2009-09-30
US7691971B2 (en) 2010-04-06
AR047263A1 (es) 2006-01-11
KR20060123759A (ko) 2006-12-04
NZ547520A (en) 2009-07-31
EP1693378A2 (en) 2006-08-23
RU2006123434A (ru) 2008-01-10
RU2336900C2 (ru) 2008-10-27
WO2005054281A2 (es) 2005-06-16
US20070218000A1 (en) 2007-09-20
AU2004294376A1 (en) 2005-06-16
ZA200604556B (en) 2007-03-28
BRPI0417309A (pt) 2007-09-11
CA2547317A1 (en) 2005-06-16
CN1890260A (zh) 2007-01-03
PL1693378T3 (pl) 2010-03-31
ATE444305T1 (de) 2009-10-15
WO2005054281A3 (es) 2005-08-04
DE602004023419D1 (de) 2009-11-12
EP1693378B9 (en) 2010-05-19
ES2334138T3 (es) 2010-03-05

Similar Documents

Publication Publication Date Title
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
NO20044940L (no) Rekombinant poxvirus som uttrykker homologe gener innsatt i det poxvirale genomet
CY1119285T1 (el) Φορεις εμβολιου αδενοϊου χιμπατζη
WO2008033375A3 (en) Long lasting drug formulations
TNSN07087A1 (en) Stable liquid formulations of plasmid dna
NO20072854L (no) Acylerte nonadepsipeptider anvendt som lysobaktinderivater
DK2010563T3 (da) Syntetisk MeCP2 sekvens til proteinsubstitutionsterapi
BR0309570A (pt) Fatores camp quiméricos para vacinação contra infecção por streptococcus
DE60142519D1 (de) Dna-expressionsvektoren
GB2458057A (en) Francisella strain for live vaccine
NO20063017L (no) Protein NMB0928 og anvendelse derav i farmasoytiske formuleringer
WO2007059931A8 (en) New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions
Wang et al. Two oral HBx vaccines delivered by live attenuated Salmonella: both eliciting effective anti-tumor immunity
NO20063020L (no) Protein NMB1125 og anvendelse derav i farmasoytiske formuleringer
DE602004024968D1 (de) Francisella-stamm für lebenden impfstoff
NO20084524L (no) Farmasoytisk sammensetning inneholdende NMB0938-protein
WO2025024776A3 (en) Compositions comprising xbp1 fragments and methods of use in gene therapy
BARZIGAR et al. Challenges and recent developments associated with vaccine antigens production against Helicobacter pylori
EP4008341A1 (en) Cra4s1 gene, encoded cra4s1 protein, and application
Basirnejad et al. Development of HCV therapeutic vaccines using Hp91 peptide and small heat shock protein 20 as an adjuvant
WO2019059817A9 (en) VACCINE BASED ON FUSION PROTEIN AND PLASMIDIC DNA
Aljohani et al. Overview of heat shock proteins (HSPs) in prokaryotes
ES2401276B1 (es) Utilización de una construcción genica y/o peptídica para la fabricación de una vacuna para la prevención y/o tratamiento de la infección causada por el virus de la peste porcina africana (vppa).
NO20083318L (no) Farmasoytiske sammensetninger inneholdende protein NMA0939
CU23419A1 (es) Proteína nmb0088 y su uso en formulaciones farmacéuticas

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application